Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, November 1, 2023
[ Wed, Nov 01st 2023
] - WOPRAI
[ Wed, Nov 01st 2023
] - WOPRAI
[ Wed, Nov 01st 2023
] - WOPRAI
[ Wed, Nov 01st 2023
] - WOPRAI
[ Wed, Nov 01st 2023
] - WOPRAI
[ Wed, Nov 01st 2023
] - WOPRAI
Tue, October 31, 2023
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
[ Tue, Oct 31st 2023
] - WOPRAI
Brian Abrahams Maintained (SRPT) at Buy with Decreased Target to $148 on, Oct 31st, 2023
Brian Abrahams of RBC Capital, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $217 to $148 on, Oct 31st, 2023.
Brian has made no other calls on SRPT in the last 4 months.
There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, 0 agree with Brian's Rating of Hold.
This is the rating of the analyst that currently disagrees with Brian
- Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $160 on, Tuesday, September 26th, 2023
